Fig. 2From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infectionsCeftolozane/tazobactam vs. piperacillin/tazobactam: Tornado diagram illustrating influence of variables on ICER (cost per discounted QALY). ICER: Incremental cost-effectiveness ratio; LOS: Length of stay; QALY: Quality-adjusted life yearBack to article page